Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors.

Quick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Smith KL, Faubion SS, Loprinzi CL, Lustberg MB.

Support Care Cancer. 2019 Dec 6. doi: 10.1007/s00520-019-05211-3. [Epub ahead of print]

PMID:
31811486
2.

Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.

Tossey JC, Reardon J, VanDeusen JB, Noonan AM, Porter K, Arango MJ.

Med Oncol. 2019 Sep 7;36(10):87. doi: 10.1007/s12032-019-1309-6.

PMID:
31494781
3.

Physical Activity After Breast Cancer Surgery: Does Depression Make Exercise Feel More Effortful than It Actually Is?

Padin AC, Wilson SJ, Bailey BE, Malarkey WB, Lustberg MB, Farrar WB, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams N, Sardesai S, Ramaswamy B, Noonan AM, Vandeusen JB, Haas GJ, Kiecolt-Glaser JK.

Int J Behav Med. 2019 Jun;26(3):237-246. doi: 10.1007/s12529-019-09778-3.

PMID:
30820922
4.

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S.

Oncotarget. 2017 Sep 1;8(44):75822-75833. doi: 10.18632/oncotarget.20616. eCollection 2017 Sep 29.

5.

Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.

Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA, Lyerly HK.

Cancer Res. 2011 Jun 15;71(12):4172-82. doi: 10.1158/0008-5472.CAN-10-3978. Epub 2011 Apr 29.

6.

In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.

Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA.

J Immunol. 2010 Mar 15;184(6):2769-75. doi: 10.4049/jimmunol.0900685. Epub 2010 Feb 8.

7.

A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia.

Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA.

Leuk Res. 2010 Feb;34(2):203-9. doi: 10.1016/j.leukres.2009.06.031. Epub 2009 Aug 5.

8.

STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo.

VanDeusen JB, Shah MH, Becknell B, Blaser BW, Ferketich AK, Nuovo GJ, Ahmer BM, Durbin J, Caligiuri MA.

Eur J Immunol. 2006 Mar;36(3):623-30.

9.

Biology and clinical impact of human natural killer cells.

Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA.

Int J Hematol. 2003 Jul;78(1):7-17. Review.

PMID:
12894845
10.

New developments in anti-tumor efficacy and malignant transformation of human natural killer cells.

VanDeusen JB, Caligiuri MA.

Curr Opin Hematol. 2003 Jan;10(1):55-9. Review.

PMID:
12483112
11.

In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.

Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA.

Blood. 2002 Nov 15;100(10):3633-8. Epub 2002 Jul 5.

PMID:
12393617
12.

Fatal leukemia in interleukin-15 transgenic mice.

Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA.

Blood Cells Mol Dis. 2001 Jan-Feb;27(1):223-30. Review.

PMID:
11358383
13.

Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.

Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA.

J Exp Med. 2001 Jan 15;193(2):219-31.

14.

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA.

J Clin Invest. 2000 Jul;106(1):117-24.

15.

Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA.

J Immunol. 1999 Apr 15;162(8):4511-20.

Supplemental Content

Loading ...
Support Center